

Pluristem Life Systems

Company Profile: **Pluristem Life Systems, Inc.** and **Pluristem Ltd.** ("Pluristem") (OTCBB:PLRS) is a life sciences driven company developing a proprietary stem cell expansion technology for the treatment of severe blood disorders. The first product targets a critical global shortfall of matched tissue for bone marrow transplantation (BMT).

Pluristem Technology: **Pluristem** has discovered and patented a process to grow and expand mesenchymal and hematopoietic stem cells (MSC, HSC). HSCs are the founding cells of the functional bone marrow (BM) and mandatory required for BMT. **Pluristem** expand HSC from umbilical cord blood (UCB) and MSC from human adult tissues (like fat or placenta). UCB is preferred over the BM as source of HSCs for reasons of reduced morbidity to donors and increased efficiency for recipients. Cell expansion is executed in an environment that mimics that of BM and does not include supplemented, potentially harmful growth factors and cytokines.

Unique Features:

1. Proprietary bioreactor (PluriX™) system that enables ex vivo expansion of HSC population in hematopoietic like microenvironment by using a spatial scaffold resembling the architecture of the BM.
2. The unique BM micro structure enable expansion of high numbers of early hematopoietic stem and progenitor cells to improve homing.
3. Use of state-of-the-art co-culture methodology in which supportive Stromal cells control HSC expansion and Co-transplantation of HSC and feeder layer cells (stroma) to improve the BMT result.
4. No use of exogenous biologics or pharmacological manipulation eliminates risk of genetic instability and allows for safer expansions of HSCs.
5. Use of CB mono-nuclear cells as the starter cohort for expansion instead of immuno-selected subpopulation of HSCs reduces regulatory constrains, increases expansion yield and decreases production costs.

Products: **PLX I** Engineered supporting tissue to improve the engraftment of Cord Blood (CB) as a replacement for BMT

PLX II Engineered graft of expanded HSC from CB and supporting tissue as a replacement for BMT

Management:
Zami Aberman – President & CEO
Yossi Keret – CFO
Dr. Shai Meretzki – Founder, CTO
Dr. Ora Burger – VP Development

Seeking:

- Strategic collaboration in clinical trials in Europe, USA and in The Far East
- Strategic alliances
- Funding join developments of new products

Pluristem
Life Systems
Giving Life a Better Chance

Contact: Mr. Zami Aberman, MATAM Tech Park, Bldg. 20, Haifa 31905, Israel.
Tel: 972-4-8501080 / Fax: 972-4-8501085
E-mail: zami@pluristem.com / Web: www.pluristem.com